Astellas Gene Therapies
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Gene Therapies sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Astellas Gene Therapies: 7 sponsored US clinical trials, 2 recruiting.
Astellas Gene Therapies sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Myotubular Myopathy, with 3 trials.
Upper-quartile sponsor footprint
Astellas Gene Therapies sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
NCT07052929
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
NCT06581146
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820
Gene Transfer Study in Patients With Late Onset Pompe Disease
NCT04174105
A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)
NCT03199469
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects
NCT02704273
A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)
NCT02231697
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Astellas Gene Therapies pipeline
2 recruiting of 7 indexed (29% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: X-Linked Myotubular Myopathy (3 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Gene Therapies: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Astellas Gene Therapies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Astellas Gene Therapies page
7 registered trials is a research-attention snapshot, not an endorsement of Astellas Gene Therapies or any single study.
- 2 of Astellas Gene Therapies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- X-Linked Myotubular Myopathy is the condition Astellas Gene Therapies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Myotubular Myopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Gene Therapies pipeline card: 7 registered trials from official public datasets.Report a data error.